Kooperativer Bibliotheksverbund

Berlin Brandenburg

and
and

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Type of Medium
Language
Year
  • 1
    Language: English
    In: Cancer, 01 February 2012, Vol.118(3), pp.797-803
    Description: BACKGROUND: Statins are widely used cholesterol-lowering agents that may have potential antitumor effect. Epidemiological studies on statin use and renal cell carcinoma (RCC) risk have been inconsistent.METHODS: The authors investigated the association between statin use and RCC risk in the Nurses' Health Study and Health Professionals Follow-Up Study. In total, 80,782 women and 37,869 men were followed for 14 years and 16 years, respectively. Regular statin use was assessed at baseline and was updated biennially during follow-up. RCC diagnosis was confirmed by medical record review.RESULTS: Two hundred seventy-seven incident RCC cases (164 women and 113 men) were identified. Compared with no current use, the multivariate relative risks of current statin use were 0.68 (95% confidence interval, 0.46-1.00) in women and 1.17 (95% confidence interval, 0.75-1.82) in men. The results for ever versus never users of statins were similar. No dose-response relation with duration of statin use and RCC risk was observed. On subgroup analyses, statin use was associated with a reduced RCC risk among women who had no history of hypertension.CONCLUSIONS: The current study indicated that statin use may be associated with a lower risk of RCC in women, although these results need to be investigated further.
    Keywords: Carcinoma ; Renal Cell ; Neoplasms ; Statin ; Prospective Studies
    ISSN: 0008-543X
    E-ISSN: 1097-0142
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Language: English
    In: International Journal of Cancer, Jan 15, 2014, Vol.134(2), p.384(13)
    Description: Byline: Toni K. Choueiri, Youjin Je, Eunyoung Cho Keywords: analgesics; aspirin; non-aspirin non-steroidal anti-inflammatory drugs; acetaminophen; kidney cancer Analgesics are the most commonly used over-the-counter drugs worldwide with certain analgesics having cancer prevention effect. The evidence for an increased risk of developing kidney cancer with analgesic use is mixed. Using a meta-analysis design of available observational epidemiologic studies, we investigated the association between analgesic use and kidney cancer risk. We searched the MEDLINE and EMBASE databases to identify eligible case-control or cohort studies published in English until June 2012 for three categories of analgesics: acetaminophen, aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs). Study-specific effect estimates were pooled to compute an overall relative risk (RR) and its 95% confidence interval (CI) using a random-effects model for each category of the analgesics. We identified 20 studies (14 with acetaminophen, 13 with aspirin and five with other NSAIDs) that were performed in six countries, including 8,420 cases of kidney cancer. Use of acetaminophen and non-aspirin NSAIDs were associated with an increased risk of kidney cancer (pooled RR: 1.28; 95% CI: 1.15-1.44 and 1.25; 95% CI: 1.06-1.46, respectively). For aspirin use, we found no overall increased risk (pooled RR: 1.10; 95% CI: 0.95-1.28), except for non-US studies (five studies, pooled RR: 1.17; 95% CI: 1.04-1.33). Similar increases in risks were seen with higher analgesic intake. In this largest meta-analysis to date, we found that acetaminophen and non-aspirin NSAIDs are associated with a significant risk of developing kidney cancer. Further work is needed to elucidate biologic mechanisms behind these findings. Supporting information: Additional Supporting Information may be found in the online version of this article Additional Supporting Information may be found in the online version of this article. CAPTION(S): Supplementary Information
    Keywords: Cancer -- Development And Progression ; Cancer -- Risk Factors ; Cancer -- Health Aspects ; Aspirin -- Health Aspects ; Cancer Research -- Health Aspects ; Kidney Cancer -- Development And Progression ; Kidney Cancer -- Risk Factors ; Kidney Cancer -- Health Aspects ; Online Health Care Information Services -- Health Aspects ; Steroidal Anti-inflammatory Agents -- Health Aspects
    ISSN: 0020-7136
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Language: English
    In: Sonpavde, G, and T K Choueiri. 2012. Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. British Journal of Cancer 107(7): 1009-1016.
    Description: Despite recent advances, metastatic renal cell carcinoma remains largely an incurable disease. Vascular endothelial growth factor and mammalian target of rapamycin inhibitors have provided improvements in clinical outcomes. High-dose interleukin 2 remains an option for highly selected patients and is associated with durable remissions in a small minority of patients. The toxicity profiles of specific agents and patient characteristics and comorbidities and costs have an important role in the current choice of therapy. Major challenges encountered in developing molecular biomarkers to guide therapy are tumour heterogeneity and standardisation of tissue collection and analysis. Although biomarkers are in their infancy of development, they should be a priority in early preclinical and clinical development in order to guide rational tailored development of emerging agents.
    Keywords: Renal Cell Carcinoma ; Biomarkers ; Prognostic ; Predictive
    ISSN: 0007-0920
    E-ISSN: 15321827
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Language: English
    In: Drugs, 2013, Vol.73(13), pp.1417-1430
    Description: Despite state of the art local therapy, a significant portion of men with high-risk prostate cancer develop progressive disease. Neoadjuvant systemic therapy prior to radical prostatectomy (RP) is an approach that can potentially maximize survival outcomes in patients with localized disease. This approach is under investigation with a wide array of agents and provides an opportunity to assess pathologic and biologic activity of novel treatments. The aim of this review is to explore the past and present role of neoadjuvant therapy prior to definitive therapy with RP in patients with high-risk localized or locally advanced disease. The results of neoadjuvant androgen-deprivation therapy (ADT), including use of newer agents such as abiraterone, are promising. Neoadjuvant chemotherapy, primarily with docetaxel, with or without ADT has also demonstrated efficacy in men with high-risk disease. Other novel agents targeting the vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), clusterin, and the immune system are currently under investigation and have led to variable results in early clinical trials. Despite optimistic data, approval of neoadjuvant therapy prior to RP in patients with high-risk prostate cancer will depend on positive results from well designed phase III trials.
    Keywords: Molecular Targeted Therapy ; Neoadjuvant Therapy ; Prostatic Neoplasms -- Therapy;
    ISSN: 0012-6667
    E-ISSN: 1179-1950
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Language: English
    In: JAMA, 03/28/2012, Vol.307(12)
    Keywords: Randomized Controlled Trials As Topic ; Androgen Antagonists -- Adverse Effects ; Cardiovascular Diseases -- Mortality ; Prostatic Neoplasms -- Drug Therapy;
    ISSN: 0098-7484
    E-ISSN: 15383598
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    In: The New England Journal of Medicine, 2017, Vol.376(4), pp.354-366
    Description: Kidney cancers have been extensively studied, and insights from an increased understanding of tumor biology have led to increases in survival rates. Therapies aimed at tumor signaling pathways and immunotherapies have improved the outlook for patients with renal cancer. Until recently, there was a dearth of effective systemic therapies for kidney cancer. The incidence of the disease steadily increased from 1975 through 2008 and leveled off after 2008. 1 – 3 Currently, it is among the 10 most frequently diagnosed cancers in men and women in the United States, with more than an estimated 62,000 new cases in 2016. 4 The prognosis has historically been poor, with current 5-year survival rates of 74% overall, decreasing to 53% among patients with locoregional (stage III) disease and 8% among patients with metastatic disease. 1 , 3 Kidney cancer is a disease of the middle-aged and elderly: . . .
    Keywords: Renal Cell Carcinoma -- Care And Treatment ; Cancer Patients -- Health Aspects ; Therapeutics -- Usage ; Drugs -- Dosage And Administration;
    ISSN: 0028-4793
    E-ISSN: 1533-4406
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    In: The New England Journal of Medicine, 2014, Vol.370(18), pp.1769-1770
    Description: Survival results are now mature for a noninferiority trial comparing pazopanib with sunitinib in renal-cell carcinoma. Median survival was 42.5 months with pazopanib and 43.6 months with sunitinib, a difference that wasnot significant. To the Editor: In the August 22 issue,1 we reported on a phase 3 trial showing the noninferiority, with respect to progression-free survival, of pazopanib versus sunitinib as first-line treatment for clear-cell, metastatic renal-cell carcinoma, as assessed by independent review. We now report the results of the final analysis of overall survival. Overall survival, a secondary end point, was defined as the time from randomization to death from any cause. The final analysis of overall survival in the intention-to-treat population was to be performed when 650 patients had died or 2 years after the last patient was enrolled. Overall survival . . .
    Keywords: Medicine;
    ISSN: 0028-4793
    E-ISSN: 1533-4406
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Language: English
    In: Cancer, Feb 1, 2011, Vol.117(3), p.656(1)
    Keywords: Prostate Cancer -- Complications And Side Effects ; Prostate Cancer -- Care And Treatment ; Prostate Cancer -- Patient Outcomes ; Cancer Recurrence -- Care And Treatment ; Cancer Recurrence -- Patient Outcomes ; Radiotherapy -- Usage
    ISSN: 0008-543X
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Language: English
    In: Cancer, 01 November 2011, Vol.117(21), pp.4846-4854
    Description: BACKGROUND: We sought to identify the costs of adjuvant therapies following radical prostatectomy (RP) and factors associated with their receipt.METHODS: We used SEER-Medicare data from 2004-2006 to identify 4247 men who underwent RP, of whom 600 subsequently received adjuvant therapies. We used Cox regression to identify factors associated with receipt of adjuvant therapies. Health care expenditures within 12 months of diagnosis were compared for RP alone versus RP with adjuvant therapies.RESULTS: Biopsy Gleason score, prostate-specific antigen, risk group, and SEER region were significantly associated with receipt of adjuvant treatments (all P〈.001). Higher surgeon volume was associated with lower odds of receiving adjuvant therapies (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.46-0.78 [P〈.001]). Factors associated with increased receipt of adjuvant therapies were positive surgical margins (HR, 3.02; 95% CI, 2.55-3.57 [P〈.001]), high-risk group versus low-risk group (HR, 7.65; 95% CI, 5.64-10.37 [P〈.001]), lymph node-positive disease (HR, 5.36; 95% CI, 3.71-7.75 [P〈.001]), and treatment in Iowa (HR, 1.93; 95% CI, 1.12-3.32 [P = .019]) and New Mexico/Georgia/Hawaii (HR, 1.92; 95% CI, 1.09-3.39 [P = .025]) versus San Francisco SEER regions (baseline). Age, race, comorbidities, and surgical approach were not associated with use of adjuvant therapies. The median expenditures attributable to postprostatectomy hormonal therapy, radiation therapy, and radiation with hormonal therapy versus were $1361, $12,040, and $23,487.CONCLUSIONS: Men treated by high-volume surgeons were less likely to receive adjuvant therapies. Regional variation and high-risk disease characteristics were associated with increased receipt of adjuvant therapies, which increased health care expenditures by 2- to 3-fold when radiotherapy was administered.
    Keywords: Prostatectomy ; Adjuvant Therapy ; Utilization ; Expenditures ; Outcomes
    ISSN: 0008-543X
    E-ISSN: 1097-0142
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Language: English
    In: BJU International, Nov, 2010, Vol.106(9), p.1249(2)
    Description: To authenticate to the full-text of this article, please visit this link: http://dx.doi.org/10.1111/j.1464-410X.2010.09732.x Byline: Leah Katz, Toni K. Choueiri (*), Joaquim Bellmunt (*) Keywords: angiogenesis; sunitinib; transitional cell carcinoma; Carbon 11-methionine; PET CT Author Affiliation: (*)Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA, USA, and ([dagger])RETICC-Htal. del Mar, Barcelona, Spain Article History: Accepted for publication 17 June 2010 Article note: Leah Katz, Tulane University School of Medicine, 801 Race Street Apt. #7408, New Orleans, LA, 70130, USA., e-mail: leahkatz85@gmail.com
    Keywords: Antineoplastic Agents -- Evaluation ; Positron Emission Tomography ; Cat Scans ; Cancer Treatment ; Cancer Metastasis ; Adenocarcinoma
    ISSN: 1464-4096
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages